Open AccessAdvances in immunotherapy for cervical cancer
Author(s) -
R. Wendel Naumann,
Charles A. Leath
Publication year - 2020
Publication title -
current opinion in oncology/current opinion in oncology, with cancerlit
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.297
H-Index - 95
eISSN - 1080-8140
pISSN - 1040-8746
DOI - 10.1097/cco.0000000000000663
Subject(s) - medicine , pembrolizumab , immunotherapy , cervical cancer , oncology , chemotherapy , active immunotherapy , immune system , cancer , regimen , clinical trial , cancer immunotherapy , immunology
Novel therapies are needed for the treatment of recurrent cervical cancer. The best chemotherapy regimen to date has a response rate of 48% with an overall survival of 17 months, with limited options for second-line chemotherapy. Immunotherapy can induce a strong immune response in cervical cancer due to retained viral antigens and is reviewed in this article.